{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T11:40:15Z","timestamp":1772797215793,"version":"3.50.1"},"reference-count":18,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T00:00:00Z","timestamp":1529366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Austin Health & Medical Research Foundation"},{"name":"Qiagen Ltd (originally Cellestis Ltd)"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Although antiviral prophylaxis is effective in preventing early cytomegalovirus (<jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>) reactivation following liver transplantation (<jats:styled-content style=\"fixed-case\">OLT<\/jats:styled-content>), it predisposes patients to late <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> after prophylaxis has ceased. Quanti<jats:styled-content style=\"fixed-case\">FERON<\/jats:styled-content>\u2013<jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">QFN<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>, Qiagen, The Netherlands) measures an individual's viral\u2010specific immune response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Fifty\u2010nine <jats:styled-content style=\"fixed-case\">OLT<\/jats:styled-content> recipients were prospectively monitored post\u2010<jats:styled-content style=\"fixed-case\">OLT<\/jats:styled-content> in an observational cohort study. <jats:styled-content style=\"fixed-case\">QFN<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> was performed at regular time\u2010points. An absolute <jats:styled-content style=\"fixed-case\">QFN<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> &lt;0.1\u00a0<jats:styled-content style=\"fixed-case\">IU<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">mL<\/jats:styled-content> was considered non\u2010reactive.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>50\/59 (84.7%) had a reactive <jats:styled-content style=\"fixed-case\">QFN<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> by M6. 38\/59 (64.4%) had antiviral prophylaxis or treatment before M6, with 31\/38 (81.6%) developing a reactive <jats:styled-content style=\"fixed-case\">QFN<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> by 6\u00a0months. Over 90% already had a reactive result as early as 3\u00a0months post transplant, 3 patients (5.08%) developed late <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> between 6\u201012\u00a0months (median 251\u00a0days)\u2014all had a non\u2010reactive M6 <jats:styled-content style=\"fixed-case\">QFN<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>. And 2\/3 experienced <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> disease. Non\u2010reactive M6 <jats:styled-content style=\"fixed-case\">QFN<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> was significantly associated with late <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">OR<\/jats:styled-content>\u00a0=\u00a054.4, <jats:styled-content style=\"fixed-case\">PPV<\/jats:styled-content>\u00a0=\u00a00.33, <jats:styled-content style=\"fixed-case\">NPV<\/jats:styled-content>\u00a0=\u00a01.00, <jats:italic>P<\/jats:italic>\u00a0=\u00a0.003).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Although only 5% of recipients developed late <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>, 2\/3 suffered <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> disease. M6 <jats:styled-content style=\"fixed-case\">QFN<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> has an excellent <jats:styled-content style=\"fixed-case\">NPV<\/jats:styled-content> for late <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>, suggesting patients who exhibit a robust ex vivo immune response at M6 can safely cease <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> monitoring. Furthermore, &gt;90% already express viral\u2010specific immunity as early as 3\u00a0months. Conceivably, antiviral prophylaxis could be discontinued early in these patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.12934","type":"journal-article","created":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T20:45:49Z","timestamp":1527626749000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Early viral\u2010specific T\u2010cell testing predicts late cytomegalovirus reactivation following liver transplantation"],"prefix":"10.1111","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9341-4792","authenticated-orcid":false,"given":"S.","family":"Sood","sequence":"first","affiliation":[{"name":"Liver Transplant Unit Victoria Austin Health University of Melbourne  Melbourne Vic. Australia"},{"name":"Department of Gastroenterology &amp; Hepatology Royal Melbourne Hospital University of Melbourne  Melbourne Vic. Australia"},{"name":"Innate Immune Laboratory St Vincent's Hospital University of Melbourne  Melbourne Vic. Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Haifer","sequence":"additional","affiliation":[{"name":"Liver Transplant Unit Victoria Austin Health University of Melbourne  Melbourne Vic. Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Yu","sequence":"additional","affiliation":[{"name":"Innate Immune Laboratory St Vincent's Hospital University of Melbourne  Melbourne Vic. Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Pavlovic","sequence":"additional","affiliation":[{"name":"Liver Transplant Unit Victoria Austin Health University of Melbourne  Melbourne Vic. Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.J.","family":"Gow","sequence":"additional","affiliation":[{"name":"Liver Transplant Unit Victoria Austin Health University of Melbourne  Melbourne Vic. Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.M.","family":"Jones","sequence":"additional","affiliation":[{"name":"Liver Transplant Unit Victoria Austin Health University of Melbourne  Melbourne Vic. Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Visvanathan","sequence":"additional","affiliation":[{"name":"Innate Immune Laboratory St Vincent's Hospital University of Melbourne  Melbourne Vic. Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.W.","family":"Angus","sequence":"additional","affiliation":[{"name":"Liver Transplant Unit Victoria Austin Health University of Melbourne  Melbourne Vic. Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.G.","family":"Testro","sequence":"additional","affiliation":[{"name":"Liver Transplant Unit Victoria Austin Health University of Melbourne  Melbourne Vic. Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,6,19]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.Supplement_7.S745"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2010.07.101"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000030141.41726.52"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(04)01202-2"},{"key":"e_1_2_7_6_1","first-page":"12","article-title":"Immunosuppressive effects of beta\u2010herpesviruses","volume":"10","author":"Boeckh M","year":"2003","journal-title":"Herpes"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.24216"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.7.2381-2386.2002"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1086\/511307"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000145989.22373.03"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000226071.12562.1a"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31822fa4b7"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e318200b9f0"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2005.00797.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31829df29d"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31828ee12e"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2006.00199.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis993"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02618.x"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftid.12934","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.12934","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T04:09:58Z","timestamp":1694837398000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.12934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,19]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1111\/tid.12934"],"URL":"https:\/\/doi.org\/10.1111\/tid.12934","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,19]]},"assertion":[{"value":"2017-12-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e12934"}}